Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

(2021) Messoud Ashina et al.   EUROPEAN JOURNAL OF NEUROLOGY

Hypertension: A new safety risk for patients treated with erenumab

(2021) Suprat Saely et al.   HEADACHE

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

(2020) Messoud Ashina et al.   CEPHALALGIA

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

(2020) Jessica Ailani et al.   HEADACHE

Efficacy and safety of eptinezumab in patients with chronic migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

(2020) Peter J Goadsby et al.   LANCET NEUROLOGY

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

(2020) Robert Croop et al.   LANCET

Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine

(2019) Jeanine L. Bussiere et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies

(2019) Tina M. Oakes et al.   HEADACHE

Vascular safety of erenumab for migraine prevention

(2019) David Kudrow et al.   NEUROLOGY

Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

(2018) Jan de Hoon et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

(2018) Christophe Depre et al.   HEADACHE

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

(2018) Paul K. Whelton et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Blocking CGRP in migraine patients – a review of pros and cons

(2017) Marie Deen et al.   JOURNAL OF HEADACHE AND PAIN

Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings

(2017) Noa Kallioinen et al.   JOURNAL OF HYPERTENSION

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people

(2014) Eleni Rapsomaniki et al.   LANCET

Migraine and cardiovascular disease: A population-based study

(2010) M. E. Bigal et al.   NEUROLOGY